×
About 74,692 results
Effect of Oral Prednisolone on Symptom Duration and Severity in Nonasthmatic Adults Wit...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817483
JAMA Hay AD, Little P et. al.

Aug 22nd, 2017 - Acute lower respiratory tract infection is common and often treated inappropriately in primary care with antibiotics. Corticosteroids are increasingly used but without sufficient evidence. To assess the effects of oral corticosteroids for acute lower respiratory tract infection in adults without asthma. Multicenter, placebo-controlled, randomized trial (July 2013 to final follow-up October 2014...

Asthma in Adults
https://www.sciencedirect.com/science/article/abs/pii/S0025712519300896?via%3Dihub
Medical Clinics of North America; Nanda A, et al

Oct 27th, 2019 - Asthma affects approximately 300 million people worldwide and approximately 7.5% of adults in the United States. Among adults, asthma results in about 10.5 million physician office visits per year and affects approximately 8.7% of blacks, 7.6% of whites, and 5.8% of Hispanics. Asthma is characterized by inflammation of airways, variable airflow obstruction, and bronchial hyperresponsiveness.3 I...

Genentech Announces FDA Approval of Xofluza (Baloxavir Marboxil) for People at High Risk of Developing Influenza-Related Complications
https://www.gene.com/media/press-releases/14817/2019-10-17/genentech-announces-fda-approval-of-xofl

Oct 16th, 2019 - Single-dose Xofluza is the first and only antiviral medicine indicated specifically for patients at high risk of developing serious complications from influenza (flu) The Centers for Disease Control and Prevention (CDC) defines people at high risk of serious flu complications as those who have conditions such as asthma, chronic lung disease, diabetes, heart disease, morbid obesity or adults ...

Global Initiative for Asthma: Global Strategy for Asthma Management & Prevention
https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf

Sep 29th, 2019 - The 2019 update of the Global Strategy for Asthma Management and Prevention incorporates new scientific information about asthma based on a review of recent scientific literature by an international panel of experts on the GINA Science Committee. This comprehensive and practical resource about one of the most common chronic lung diseases worldwide contains extensive citations from the scientifi...

Can Mild Asthma Be Managed with Only As-Needed Inhaled Steroids Plus a Bronchodilator?
https://www.jwatch.org/na49830/2019/09/26/can-mild-asthma-be-managed-with-only-needed-inhaled

Sep 25th, 2019 - David J. Amrol, MD reviewing Hardy J et al. Lancet 2019 Sep 14 Gauthier M and Wenzel SE. Lancet 2019 Sep 14

Nucala is the first biologic approved in the US for six to 11-year-old children with severe eosinophilic asthma
https://www.gsk.com/en-gb/media/press-releases/nucala-is-the-first-biologic-approved-in-the-us-for-six-to-11-year-old-children-with-severe-eosinophilic-asthma/

Sep 11th, 2019 - GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for use in children as young as six years old who are living with severe eosinophilic asthma. Nucala is the only targeted biologic to be approved for the condition in the six to 11-year age group in the US.

Risk of Acute Myocardial Infarction and Ischemic Stroke in Patients with Asthma Exacerbation: A Population-Based, Self-Controlled Case Series Study
https://www.sciencedirect.com/science/article/abs/pii/S2213219819306178?via%3Dihub
The Journal of Allergy and Clinical Immunology: In Practice; Raita, Y. et. al.

Jul 15th, 2019 - Background Patients with asthma have a high incidence of acute myocardial infarction and ischemic stroke. Objective To investigate the acute effect of asthma exacerbation on these cardiovascular events. Methods Using population-based inpatient data of 3 geographically diverse US states (Florida, Nebraska, and New York) during the period 2011 to 2014, we conducted a self-controlled case...

Teva Announces FDA Approval of AirDuo® Digihaler™ (fluticasone propionate 113 mcg and salmeterol 14 mcg) Inhalation Powder
https://tevapharm.com/news/teva_announces_fda_approval_of_airduo_sup_reg_sup_digihaler_trade_fluticasone_propionate_113_mcg_and_salmeterol_14_mcg_inhalation_powder_07_19.aspx

Jul 14th, 2019 - Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved AirDuo® Digihaler™ (fluticasone propionate 113 mcg and salmeterol 14 mcg) Inhalation Powder, a combination therapy digital inhaler with built-in sensors that connects to a companion mobile application to provide information on inhaler use to people with asthma....

Clinical Trials | NUCALA (mepolizumab)
https://gskpro.com/en-us/products/nucala/for-severe-eosinophilic-asthma/efficacy/

Jun 26th, 2019 - NUCALA (mepolizumab) has clinical data on exacerbation reduction. Learn about NUCALA for patients with severe eosinophilic asthma.

Atopic dermatitis/Eczema | DermNet NZ
https://www.dermnetnz.org/topics/atopic-dermatitis/

Jun 24th, 2019 - Atopic dermatitis is a chronic, itchy skin condition that is very common in children but may occur at any age. It is also known as eczema and atopic eczema and was formerly known as Besnier prurigo. It is the most common form of dermatitis. Atopic dermatitis usually occurs in people who have an 'atopic tendency'. This means they may develop any or all of three closely linked conditions; atop...

Rate of life-threatening childbirth complications increasing sharply across U.S. racial, ethnic groups
https://www.nih.gov/news-events/news-releases/rate-life-threatening-childbirth-complications-increasing-sharply-across-us-racial-ethnic-groups

May 2nd, 2019 - Racial and ethnic disparities in severe maternal morbidity — life-threatening maternal complications associated with childbirth — have persisted and increased at high rates among U.S. women, according to an analysis of nearly 20 years of California hospital records funded by the National Institutes of Health. Known risk factors for these complications — such as blood pressure disorders, asthma ...

Asthma Data, Statistics, and Surveillance
https://www.cdc.gov/asthma/asthmadata.htm

Mar 24th, 2019 - The latest national and state data on the burden of asthma among children and adults.

The Effects of Early Nutritional Interventions on the Development of Atopic Disease in Infants and Children: The Role of Maternal Dietary Restriction, Breastfeeding, Hydrolyzed Formulas, and Timing...
https://doi.org/10.1542/peds.2019-0281

Mar 17th, 2019 - This clinical report updates and replaces a 2008 clinical report from the American Academy of Pediatrics, which addressed the roles of maternal and early infant diet on the prevention of atopic disease, including atopic dermatitis, asthma, and food allergy. As with the previous report, the available data still limit the ability to draw firm conclusions about various aspects of atopy prevention ...

Asthma More Common in Opioid-Dependent Patients
https://www.medpagetoday.com/meetingcoverage/aaaai/78193
Boyles, S.

Feb 23rd, 2019 - The prevalence of asthma was nearly twice as high as the national average in a cohort of opioid-dependent patients receiving acute care at an inner city hospital in a New York City borough, with female sex more closely linked to higher asthma risk than male sex, researchers reported here.

Coverage from the American Academy of Allergy, Asthma and Immunology (AAAAI) 2019 Meeting
https://www.medscape.com/viewcollection/34847

Feb 21st, 2019 - American Academy of Allergy, Asthma and Immunology (AAAAI) 2019 Meeting: Read clinically focused news coverage of key developments from AAAAI 2019

The Asthma Controller Step-down Yardstick
https://linkinghub.elsevier.com/retrieve/pii/S1081120618315047
Chipps, B.,et al

Dec 10th, 2018 - Asthma guidelines recommend a control-based approach to disease management in which the assessment of impairment and risk is linked to step-based therapy. Using this model, controller treatment is adjusted—upward or downward—according to a patient's level of asthma control over time.

Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma – a systematic review and meta-analysis
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282428/
European Clinical Respiratory Journal;

Nov 6th, 2018 - Background: New, complex, and expensive therapies targeting Interleukin-5 (IL-5) to treat severe eosinophilic asthma are emerging. Objective: To assess efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab for treating severe eosinophilic asthma. Design: A systematic review and meta-analysis on randomized, placebo-controlled, clinical trials elucidating two cri...

Clinical Guideline for the Diagnosis, Evaluation and Management of Adults and Children with Asthma
https://www.health.ny.gov/publications/4750.pdf

Nov 3rd, 2018 - Consider a diagnosis of asthma and perform spirometry if any of these indicators are present :The symptoms of dyspnea, cough and/or wheezing, especially nocturnal, difficulty breathing or chest tightness

Eosinophilic Asthma | Apfed
https://apfed.org/about-ead/eosinophilic-asthma/

Jun 25th, 2018 - For decades physicians have understood that a diagnosis of asthma requires further description because attacks of wheezing and shortness of breath can be associated with several underlying diseases. For example, patients allergic to animal dander, such as cat dander, who have animals as pets, may suffer from chronic severe asthma. Identification of patients with this form of asthma (referred to...

Asthma for Healthcare Professionals | CDC
https://www.cdc.gov/asthma/healthcare.html

Jun 18th, 2018 - Vital Signs: Asthma in Children – United States, 2001-2016 Free continuing education (CE) activity that describes trends and demographic differences in health outcomes and healthcare use for childhood asthma, based on a CDC analysis of asthma data from the 2001-2016 National Health Interview Survey for children 17 years and younger.This activity is intended for pediatricians, pulmonologists, ...